Catalog No.
Product Name
Application
Product Information
Citations
-
TTBK1 Inhibitor
TTBK1-IN-4 is a potent inhibitor of TTBK1, exhibiting a biochemical IC₅₀ of 2.3 nM and a cellular IC₅₀ of 42 nM. This compound serves as a valuable tool for investigating the role of TTBK1 in neurodegenerative diseases, particularly Alzheimer's disease. Researchers can utilize TTBK1-IN-4 to explore its potential therapeutic implications and the underlying mechanisms associated with TTBK1 activity. -
Tau Disaggregator
D-TLKIVWC functions as a tau fibril disaggregator, effectively reducing tau aggregation through the disruption of intermolecular hydrogen bonds via a stress-release mechanism. Its low immunogenicity and anti-degradation properties make it a valuable tool in research. D-TLKIVWC is particularly relevant for studies surrounding amyloid diseases, including Alzheimer's disease, facilitating insights into tau-related pathologies. -
Norepinephrine metabolite
Dopegal is a metabolite of norepinephrine that primarily targets asparagine endopeptidase. It is known to induce pathological tau aggregation in the locus coeruleus, making it an important tool in studying neurodegenerative diseases. Research applications include the investigation of tau pathology and the mechanisms underlying neurodegeneration associated with norepinephrine dysregulation. -
Tau fragment
Tau Peptide (245-274) (Repeat 1 Domain) is a specific fragment of the Tau protein that serves as a crucial target in neurodegenerative research. This peptide is involved in the formation of neurofibrillary tangles, which are characteristic of Alzheimer's disease and other tauopathies. It can be used in studies investigating tau aggregation and toxicity, as well as in the development of therapeutics aimed at modulating tau pathology. -
Tau fragment
Tau Peptide (294-305) (human) is a biologically active fragment of the Tau protein that plays a critical role in neurodegenerative diseases, particularly in Alzheimer’s disease. This peptide is instrumental in studying tau pathology, including tau aggregation and neurofibrillary tangles. It serves as an important tool for researchers investigating the mechanisms of tau-related neurodegeneration and developing potential therapeutic approaches. -
Tau fragment
Tau Peptide (45-73) (Exon 2/Insert 1 Domain) is a fragment of the Tau protein that plays a crucial role in stabilizing microtubules. This peptide is often used in research studies focusing on neurodegenerative diseases, particularly Alzheimer's disease, where Tau pathology is implicated. It serves as a valuable tool for investigating Tau aggregation, cellular interactions, and the effects of post-translational modifications on Tau function. -
Tau-aggregation Inhibitor
Tau-aggregation-IN-5 is a potent inhibitor of Tau aggregation with an EC50 of 0.31 μM, targeting P4HB covalently. This compound induces mild endoplasmic reticulum (ER) stress, making it valuable for investigating neurodegenerative diseases, including Alzheimer's and Pick's diseases. Its unique mechanism allows for detailed studies of Tau pathology and potential therapeutic strategies. -
Tau Protein Aggregation Inhibitor
ACI-3024 is a potent, orally active inhibitor of Tau protein aggregation. It effectively reduces the β-sheet content and seeding properties of abnormal Tau proteins associated with various Tauopathies, thereby significantly alleviating Tau-induced neurodegeneration and neuroinflammation in cellular models. ACI-3024 serves as a valuable tool for research into neurodegenerative diseases. -
Polypeptide
Tau Peptide (274-288) is a polypeptide that plays a significant role in neurobiology through its interaction with tau protein. This peptide is widely utilized in research applications focused on protein-protein interactions, functional analyses, and epitope mapping. It serves as a valuable tool in the exploration of tau-related pathologies, aiding in the understanding of neurodegenerative diseases such as Alzheimer's. -
Tau fragment
Tau Peptide (306-336) (Repeat 3 Domain) targets the Tau protein, specifically the repeat domain that plays a crucial role in microtubule stabilization. This peptide fragment facilitates studies on Tau's involvement in neurodegenerative diseases, particularly Alzheimer's disease, by helping to elucidate the mechanisms of Tau aggregation and function. It serves as a valuable tool for researchers investigating Tau-related pathology and potential therapeutic interventions. -
TAU Inhibitor
TAU-IN-3 is an orally active inhibitor of tau protein. This compound effectively inhibits the expression of the MAPT exon 10 DDPAC mutant gene in HeLa cells, demonstrating an IC50 of 0.6 µM. It reduces the 4-repeat/3-repeat MAPT mRNA ratio in cells with wild-type or DDPAC minigenes and inhibits the insertion of endogenous MAPT exon 10, subsequently decreasing the production of 4-repeat tau protein. TAU-IN-3 also modulates tau splicing in htau mice, yielding improvements in associated behavioral phenotypes, making it a valuable reagent for studies on neurodegenerative diseases. -
Tau Fibrilization Inhibitor
Ac-Val-Gln-aIle-Val-aTyr-Lys-NH2 is a N-amino peptide that selectively inhibits tau protein fibrilization. This compound effectively prevents the cellular seeding of endogenous tau by binding to both monomeric and fibrillar forms of extracellular tau. Ac-Val-Gln-aIle-Val-aTyr-Lys-NH2 is valuable for research in neurodegenerative diseases, including Alzheimer's disease, providing insight into tau pathology and potential therapeutic interventions. -
Tau Inhibitor
TAU-IN-6 is a selective inhibitor of Tau protein misfolding and aggregation. It effectively inhibits the formation of stress granules comprising Tau and TIA1, making it a valuable tool in studying Tau pathology. This compound is particularly relevant for research related to Alzheimer's disease and other tauopathies. -
Aggregated Tau Protein Binder
JNJ-64326067 is an aggregated tau protein binder with a Ki of 2.4 nM, demonstrating significant blood-brain barrier permeability. This compound selectively targets aggregated tau protein while exhibiting no binding affinity for aggregated β-amyloid or off-target interactions with various receptors, ion channels, transporters, kinases, and monoamine oxidases. JNJ-64326067 is a valuable tool for investigating the pathophysiology of Alzheimer's disease and exploring potential therapeutic strategies. -
Salicylate Lithium Salt
Lithium salicylate is a lithium salt of salicylic acid that primarily targets tau phosphorylation. It exhibits potential therapeutic effects by reducing tau hyperphosphorylation, thereby alleviating related pathologies in models of Alzheimer's disease. This compound is valuable for research into Alzheimer's mechanisms and potential treatments. -
TTBK1/TTBK2 Inhibitor
TTBK1/2-IN-2 is a selective inhibitor of Tau tubulin kinase 1 (TTBK1) and TTBK2, exhibiting IC50 values of 384 nM and 175 nM, respectively. This compound has been shown to significantly influence ciliogenesis in human induced pluripotent stem cells (iPSCs), making it a valuable tool for studying the roles of TTBK1 and TTBK2 in cellular processes and related pathologies. Its potent inhibitory activity positions TTBK1/2-IN-2 as an important reagent for research in neurodegenerative diseases and cilia-related disorders. -
Tau fragment
Tau Peptide (379-408) is a specific fragment of the tau protein, which is integral to neurodegenerative research, particularly in the study of tauopathies. This peptide serves as a crucial tool for understanding tau aggregation, neurofibrillary tangles formation, and synaptic dysfunction. Its applications include investigating mechanisms of tau-related pathologies and evaluating therapeutic interventions targeting tau misfolding and toxicity. -
Tau Peptide
Acetyl-PHF5 amide is a tau peptide that demonstrates amyloidogenic properties, facilitating the polymerization into filamentous structures. This compound is valuable for research into tau-related pathologies, such as Alzheimer's disease, and is used to study the mechanisms of tau aggregation and neurodegeneration. Its ability to replicate key features of tau protein behavior makes it an essential tool for investigating therapeutic strategies targeting tauopathies. -
Tau-aggregation Inhibitor
Tau-aggregation-IN-3 is a potent inhibitor of Tau protein aggregation, demonstrating an EC50 value of 4.816 μM in cell-based assays. This compound is valuable for research into neurodegenerative diseases, particularly Alzheimer's disease, where Tau aggregation plays a critical role in pathogenesis. Its ability to inhibit Tau aggregation makes it a useful tool for investigating therapeutic strategies aimed at Tau-related mechanisms. -
Tau Aggregate Ligand
Tau ligand-2 is a selective tau aggregate ligand with a Ki value of 0.99 nM. Radiolabeled with fluorine-18, this compound serves as a positron emission tomography (PET) tracer, enabling the visualization of tau pathology. Tau ligand-2 is particularly relevant for research on Alzheimer's disease and other tauopathies, aiding in the understanding of neurodegenerative processes. -
TAU Inhibitor
TAU-IN-2 is a selective TAU inhibitor that demonstrates an EC50 value of 7.7 nM. This compound is primarily utilized in the investigation of neurodegenerative diseases, making it a valuable tool for researchers studying the role of TAU protein aggregation in conditions such as Alzheimer’s disease. Its potent inhibitory action allows for detailed exploration of TAU-related pathways and potential therapeutic interventions. -
Tau Protein Inhibitor
LDN-193665 is a potent inhibitor of Tau kinases, demonstrating significant tauopathy-modifying activity. This compound effectively reduces Tau phosphorylation and decreases Sarkosyl-insoluble Tau levels in preclinical models. Additionally, LDN-193665 has been shown to enhance cognitive function, restoring memory in animal studies and highlighting its potential application in researching tauopathies. -
Anti-MAPT Antibody
Moponetug is a humanized IgG1κ antibody specifically targeting microtubule-associated protein tau (MAPT). This antibody plays a crucial role in studying tau-related neurodegenerative diseases, including Alzheimer's disease and other tauopathies. It is designed for applications such as immunohistochemistry, western blotting, and flow cytometry, facilitating the investigation of tau protein dynamics and pathology in various research contexts. -
TTBK1/TTBK2 Inhibitor
TTBK1/2-IN-1 is a selective inhibitor of Tau tubulin kinases TTBK1 and TTBK2, demonstrating IC50 values of 816 nM and 384 nM, respectively. This compound effectively interferes with tau phosphorylation, making it a valuable tool in research focused on tauopathies and neurodegenerative diseases. Its application can aid in understanding the role of TTBK1 and TTBK2 in cellular processes and serve as a basis for the development of therapeutics targeting tau-related pathologies. -
TTBK1 Inhibitor
TTBK1-IN-3 is a selective inhibitor of TTBK1, exhibiting a biochemical IC₅₀ of 18 nM and a cellular IC₅₀ of 259 nM. This compound is valuable for investigating the role of TTBK1 in Alzheimer's disease research. Its potency allows for detailed studies on the enzymatic pathways involved in neurodegenerative processes. -
Tau fragment
Tau Peptide (1-16) (human) is a fragment of the Tau protein, primarily targeting Tau-mediated pathways involved in neurodegenerative diseases. This peptide is crucial for studying the role of Tau in processes such as microtubule stabilization and neurofibrillary tangle formation. It serves as an important tool for research applications focused on Alzheimer's disease and other tauopathies. -
Tau/pre-miRNA-146a Inhibitor
MG-1102 is a first-in-class dual binder targeting both monomeric tau and pre-miRNA-146a. It exhibits specific inhibition of pre-miRNA-146a, with IC50 values of 0.21 mM for double-labeled and 0.36 mM for mono-labeled forms. Additionally, MG-1102 shows a binding affinity for tau monomers, characterized by a Kd of 3.21 mM as determined by surface plasmon resonance (SPR). This compound serves as a potential multi-target-directed ligand (MTDL) for research applications related to Alzheimer’s disease. -
Tau fragment
Tau Peptide (74-102) (Exon 3/Insert 2 Domain) is a specific fragment of the tau protein that plays a crucial role in stabilizing microtubules in neurons. This peptide is instrumental in research focusing on tauopathies, including Alzheimer’s disease, where tau aggregation and dysfunction are key pathological features. By utilizing this peptide, researchers can investigate tau-related mechanisms and develop potential therapeutic strategies for neurodegenerative disorders. -
Tau Protein Aggregation Inhibitor
Hydromethylthionine dihydrobromide is a potent inhibitor of tau protein aggregation. By interacting with tau proteins, it effectively prevents the formation of neurotoxic aggregates, thereby reducing neurodegeneration. This compound is valuable for research involving Alzheimer's disease and other tau-related disorders, providing insights into the mechanisms of neurodegenerative processes. -
TTBK1 Inhibitor
TTBK1-IN-5 is a selective inhibitor of TTBK1, exhibiting an IC₅₀ value of 239 nM. It is designed for studies investigating the role of TTBK1 in neurodegenerative disorders, particularly Alzheimer's disease. This compound facilitates research aimed at understanding TTBK1's biological function and its potential as a therapeutic target in Alzheimer's pathology. -
Antisense Oligonucleotide
Inotersen sodium is a 2′-O-methoxyethyl-modified antisense oligonucleotide that targets the transthyretin (TTR) RNA transcript to inhibit the production of TTR protein. This reduction in TTR levels makes Inotersen sodium a valuable tool for studying hereditary TTR amyloidosis polyneuropathy. Its mechanism of action provides insight into potential therapeutic strategies for related disorders. -
TTR Inhibitor
Eplontersen sodium is a triantennary N-acetyl galactosamine (GalNAc3-7a)-conjugated antisense oligonucleotide that targets transthyretin (TTR) mRNA, effectively inhibiting the production of both variant and wild-type TTR protein. By reducing TTR levels, Eplontersen sodium plays a crucial role in addressing conditions associated with amyloid TTR (ATTR) amyloidosis, where misfolded TTR leads to the formation of amyloid fibrils affecting the heart and peripheral nerves. This compound is pivotal for research in therapeutic strategies aimed at managing hereditary and wild-type forms of amyloidosis. -
TTR Inhibitor
Inotersen is a 2'-O-methoxyethyl-modified antisense oligonucleotide targeting transthyretin (TTR) to inhibit its production. By binding to TTR mRNA, Inotersen promotes RNase H1-mediated degradation, leading to a decrease in both mutant and wild-type TTR synthesis in the liver. This reduction significantly mitigates amyloid fiber deposition, making Inotersen a valuable tool in research focused on hereditary transthyretin amyloidosis, including its related complications such as polyneuropathy and cardiomyopathy. Caution is advised, as high doses may lead to specific toxicities, including inflammation or tumor development in certain animal models. -
Transthyretin Stabilizer
Acoramidis, also known as AG10, is a selective kinetic stabilizer that targets wild-type and V122I transthyretin (TTR). It is utilized in research focused on transthyretin amyloidosis, facilitating the understanding of its molecular mechanisms and potential therapeutic strategies. Through its stabilization of TTR, Acoramidis contributes valuable insights into the treatment of amyloid-related diseases. -
TTR Inhibitor
Eplontersen is a triantennary N-acetyl galactosamine (GalNAc3-7a) conjugated antisense oligonucleotide that selectively targets transthyretin (TTR) mRNA. By inhibiting the synthesis of both variant and wild-type TTR proteins, Eplontersen plays a crucial role in disrupting the misfolding of TTR, which contributes to the formation of amyloid fibrils associated with ATTR amyloidosis. This compound is valuable for research applications focused on amyloid-related diseases and exploring therapeutic strategies for TTR-related pathologies. -
Transthyretin Stabilizer
Acoramidis hydrochloride is a selective kinetic stabilizer of wild-type and V122I transthyretin (TTR). This compound is actively researched for its potential to inhibit the formation of amyloid fibrils associated with transthyretin amyloidosis. Its application in preclinical and clinical studies aims to further understand TTR's role in disease pathways and to develop effective therapeutic strategies. -
WT-TTR Inhibitor
WT-TTR Inhibitor 1 is a selective inhibitor of wild-type Transthyretin (WT-TTR), demonstrating 29.05% inhibition at a concentration of 100 μM. This compound is valuable for research applications focused on amyloidogenesis and associated diseases, including familial amyloid polyneuropathy. Its demonstrated inhibitory capacity makes it a potential tool for studying the effects of WT-TTR on protein misfolding and aggregation. -
TTR Amyloid Fibril Formation Inhibitor
Dichlorophenyl-ABA is a potent inhibitor of transthyretin (TTR) amyloid fibril formation. It demonstrates the ability to significantly inhibit aggregate formation by over 80% in TTR L55P-expressing cells. This compound is valuable for research focused on amyloid-related disorders, particularly in understanding TTR's role in amyloidosis. -
TTR Stabilizer
TTR Stabilizer 1 is a potent stabilizer of Transthyretin (TTR) with an EC50 value of 0.031 μM. This compound enhances TTR stability, making it an important tool for research into amyloid diseases associated with TTR misfolding. Its ability to modulate TTR functional integrity offers significant potential for studies focused on therapeutic interventions in related pathologies. -
TTR Inhibitor
Transthyretin-IN-3 is a benzofuran analogue that selectively inhibits transthyretin (TTR) by binding to its thyroxine binding site. This compound effectively disrupts amyloid aggregation, demonstrating an IC50 value of 5.0±0.2 μM. By preventing the dissociation of TTR tetramers into unstable monomers, Transthyretin-IN-3 shows potential in research applications related to amyloid-related diseases. -
siRNA Agent
Revusiran is a first-generation short interfering RNA (siRNA) that targets and inhibits transthyretin (TTR) mRNA. By reducing TTR expression, Revusiran is instrumental in studying TTR-mediated amyloidosis and its associated pathologies. This reagent serves as a valuable tool for researchers investigating the molecular mechanisms of amyloid formation and potential therapeutic interventions. -
ATTR Inhibitor
Transthyretin-IN-4 is a bivalent inhibitor targeting transthyretin (TTR) amyloidosis with a bIC50 of 0.09 µM. This compound is instrumental in researching fatal heart failure with preserved ejection fraction (HFpEF) and associated fatal arrhythmias. Its ability to modulate TTR dynamics makes it a valuable tool for investigating the pathophysiology of TTR-related diseases. -
Transthyretin Inhibitor
Transthyretin-IN-2 is a transthyretin (TTR) inhibitor that effectively targets TTR amyloidosis, demonstrating an IC50 value of 1.31 μM. This compound plays a crucial role in the study of TTR-related amyloid diseases, providing valuable insights into therapeutic approaches for managing amyloidosis. Researchers may utilize Transthyretin-IN-2 for investigations into the biochemical pathways of TTR misfolding and aggregation. -
TTR Stabilizer
TTR Stabilizer L6 is a specific compound that binds to the T4 binding pocket of transthyretin (TTR), effectively preventing its dissociation into monomers. This stabilization is crucial for maintaining TTR's functional integrity, making L6 a valuable tool in the study of familial amyloid polyneuropathy. Its ability to modulate TTR behavior positions it as a promising candidate for research focused on amyloid-related diseases. -
α-synuclein Aggregation Inhibitor
SynuClean-D is an inhibitor of α-synuclein aggregation that disrupts the formation of mature amyloid fibrils, preventing their propagation. This compound has demonstrated efficacy in abolishing degeneration of dopaminergic neurons in animal models of Parkinson’s disease. SynuClean-D is valuable for studying the mechanisms of neurodegenerative disorders and developing potential therapeutic strategies. -
α-Synuclein Oligomerization Inhibitor
Minzasolmin (UCB0599; (R)-NPT200-11) is an orally bioavailable compound that functions as an α-synuclein oligomerization inhibitor. By selectively binding to misfolded α-synuclein intermediates, it disrupts aggregation and fibril formation, thereby stabilizing their conformation. This mechanism effectively reduces the formation of pathological oligomers and blocks neurotoxic signaling, contributing to decreased α-synuclein accumulation in the brain. Preclinical studies demonstrated that Minzasolmin significantly improved motor deficits and reduced neuroinflammation, as well as α-synuclein-related pathology in transgenic mouse models. -
PROTAC α-Synuclein Degrader
PROTAC α-synuclein degrader 5 is a potent small-molecule degrader targeting α-synuclein aggregates through the PROTAC mechanism. This compound demonstrates a DC50 value of 7.51 μM and achieves a maximal degradation rate (Dmax) of 89%. Incorporating the probe molecule sery308 and E3 ligase ligands, this degrader is suitable for research on neurological diseases, facilitating studies on the pathophysiology of synucleinopathies. -
α-Synuclein Aggregation Inhibitor
PBT434 mesylate is an orally active α-synuclein aggregation inhibitor that effectively penetrates the blood-brain barrier. This compound functions as an iron chelator, modulating transcellular iron trafficking while inhibiting iron-mediated redox activity and the aggregation of α-synuclein. PBT434 mesylate demonstrates neuroprotective effects by preventing the loss of neurons in the substantia nigra pars compacta. It holds promise for advancing research in Parkinson’s disease. -
α-synuclein Degrader
PROTAC α-synuclein degrader 3 is a selective degrader targeting α-synuclein via the ubiquitin-proteasome system. This compound facilitates the ubiquitination and subsequent degradation of α-synuclein, making it a valuable tool for researching Parkinson's disease mechanisms. Its unique design incorporates specific ligands and linkers to optimize efficacy in targeted protein degradation, aiding investigations into therapeutic strategies for neurodegenerative disorders. -
ASYN Misfolding Inhibitor
(Rac)-Minzasolmin is an alpha-synuclein (ASYN) misfolding inhibitor that effectively penetrates the blood-brain barrier. By targeting the early stages of ASYN aggregation, (Rac)-Minzasolmin promotes the reversion of membrane-bound oligomers back to their monomeric form, thereby preventing pathological aggregation. This compound has demonstrated efficacy in reducing ASYN deposition in the retina and improving neuro-pathological indicators in two α-synuclein transgenic mouse models. It is a valuable tool for research on Parkinson's disease and dementia with Lewy bodies.
